$CC

HOSTETTER SHANE purchased $50K of CC

HOSTETTER SHANE (Chief Financial Officer) purchased 3,350 shares of Chemours Co (CC) at $14.94 on 2026-08-06.

Original reporting
SEC EDGAR · HOSTETTER SHANE
Published Aug 10, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 10, 2026, 8:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CC
Neutral
low confidence
Mentioned
$CC
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CCNeutralLow
01

Why it matters

A CFO open-market purchase of $50,049 worth of CC shares is disclosed, but there is no accompanying operational or financial update in the text.

02

Market read

Traders may note the insider buy as a small sentiment input, but the filing alone is unlikely to drive a major repricing without other catalysts.

03

What to watch

The filing states no pre-arranged 10b5-1 plan, but it still provides no context on motivation, timing constraints, or whether other insiders are buying/selling.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-10 after-hours (Form 4 timestamp 16:30 ET)

Background

The article is a SEC Form 4 insider transaction disclosure for Chemours (CC).

Company-level read

Ticker impact

$CCNeutralLow confidence
Context

Chemours CFO Shane Hostetter filed a Form 4 showing an open-market purchase of 3,350 shares at $14.94 on 2026-08-06.

Expected impact

Limited near-term impact; any effect is likely sentiment-driven and small.

Evidence & confidence

Form 4 insider purchases can be informative, but this transaction size and lack of accompanying company-specific news make it unlikely to move the stock materially on its own.

Market effects

No clear sector read-through from a single CFO open-market purchase.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine liquidity or diversification activity, and this Form 4 does not indicate a planned change in company outlook.

Key entities

  • Chemours Co

    Company whose insider transaction is disclosed via Form 4.

  • Shane Hostetter

    Chief Financial Officer reporting an open-market purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CCHigh

Why is Chemours stock sliding today?

Chemours (CC) stock fell 2.3% in pre-market trading after Mizuho downgraded it to Neutral and cut its price target to $15. RBC also downgraded it to Sector Perform, reducing its target to $14. Both analysts cited concerns over slower earnings growth and weak demand in key markets. The stock has lost over 40% in six months, trading near its 52-week low.

$CCMed

Mizuho downgrades Chemours stock rating on refrigerants delay

Mizuho downgraded Chemours (NYSE:CC) to Neutral from Outperform, lowering its price target to $15 from $18. The downgrade reflects slower-than-expected earnings growth from new refrigerants and concerns about titanium dioxide pigment market stability. Chemours' stock is down over 41% in the past six months, trading at $13.20. The company reported mixed Q2 2026 results, missing earnings and revenue estimates, and settled PFAS-related claims with North Carolina.

$CCHigh

Chemours falls as RBC downgrades stock on persistent TiO2 weakness

Chemours Co (CC) shares dropped 2.5% premarket after RBC downgraded it to Sector Perform, citing weak TiO2 demand and reduced growth expectations. RBC cut its price target to $14 from $22 and lowered EBITDA estimates for Q3 and FY26-FY27, citing macro pressures and project delays. The analyst sees limited near-term upside and a fully valued stock at current levels.

$CCMedAI 8/10

Corporations Are Dodging Accountability for PFAS Contamination Around the Globe

Chemours, a chemical company, has been linked to PFAS contamination in the Cape Fear River, North Carolina, affecting drinking water and health. The state reached a $590M settlement with Chemours for damages. PFAS contamination has also been reported near Chemours' facilities worldwide, raising concerns about global environmental and health impacts. Chemours inherited cleanup liabilities from its former parent company, DuPont, after a 2015 spin-off.